[Interperitoneal alpha-2b interferon for advanced ovarian cancer in complete remission or minimal residual disease].
P L
PL
Cherchi
S
S
Dessole
F
F
Esposito
G
G
Ambrosini
F Z
FZ
El Qandil
A
A
Ambrosini
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007274:Injections, Intraperitoneal; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D010052:Ovariectomy; D011994:Recombinant Proteins; D012074:Remission Induction
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins